Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Joins Canada's National Access Project

NEW YORK (GenomeWeb) – Illumina has joined Canada's National Access Project consortium. 

Illumina's technology will be used to sequence DNA collected through the project, which is managed by the Personalized Medicine Initiative. Testing for the project is being carried out by Vancouver, British Columbia-based molecular diagnostics firm Contextual Genomics. 

The National Access Project's goal is to make genomic testing a standard in cancer care and to enable a personalized medicine approach to treating the disease. 

Through the project about 2,000 patients will receive a 90-mutation cancer genomic test for free. The first phase of the project is currently underway and is retrospectively mapping tumors to identify mutations for about 500 patients. Each identified mutation is actionable with current therapies or therapies in Phase III studies. 

In the second phase, the project will be expanded to include about 1,500 patients to prospectively evaluate and match specific tumor types with about 40 therapy options. 

Funding and technical assistance for the project is being provided by Illumina, AstraZeneca, Pfizer, Sanofi, and others.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.